Mizuho Initiates Coverage On EyePoint Pharmaceuticals with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has initiated coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and a price target of $20.
November 02, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received a Buy rating from Mizuho with a price target of $20.
The Buy rating and price target of $20 announced by Mizuho for EyePoint Pharmaceuticals indicates a positive outlook for the company. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100